Analysis of a murine B cell lymphoma, CH44, with an associated non-neoplastic T cell population. I. Proliferation of normal T lymphocytes is induced by a secreted product of the malignant B cells. by unknown
American Journal of Pathology, Vol. 133, No. 3, December 1988
Copyright © American Association of Pathologists
Analysis ofa Murine B Cell Lymphoma, CH44,
with an Associated Non-Neoplastic
T Cell Population
I. Proliferation ofNormal T Lymphocytes Is Induced by a
Secreted Product ofthe Malignant B Cells
PATRICIA B. WILLOUGHBY, PhD,*
J. CHARLESJENNETTE, MD,t and
GEOFFREY HAUGHTON, PhD*
A non-neoplastic T cell population associated with a
murine monoclonal B cell malignancy, CH44, was an-
alyzed. Immunofluorescence on cell suspensions and
immunoperoxidase staining on tissue sections using
monoclonal antibodies to the antigens Thyl.2, Ly-1,
L3T4, and Lyt-2 confirmed the presence of both TH
(Ly-1/L3T4+, Lyt-2-) and TC/S (Ly-1/L3T4-, Lyt-2+) T
cell subpopulations. The non-neoplastic T cells were
present in both a 0.6 and 2.1 g CH44-bearing spleen. T
cells, not normally in liver in significant numbers,
were found in liver tissue when the CH44 tumor cells
were present. These data implied an active prolifera-
tion ofthe T cell populations within tissues containing
the malignant B cells. Supernatant from an in vitro-
adapted cell line ofCH44 (CH44.LX) was tested for its
ability to induce proliferation ofnormal murine sple-
IMMUNOPHENOTYPING OF HUMAN lympho-
mas has established that most involved tissues contain
mixtures of lymphocytes, both B cells and T cells' 2
with one population being neoplastic and the other
non-neoplastic. The majority of non-Hodgkin's lym-
phomas (NHL, 70-80%) are of B cell origin.3 Lym-
phomas are classified as being of B cell origin based
mainly on restricted heavy and light chain expression
despite the high, and sometimes predominant, num-
bers of T cells.",4 Several groups have analyzed the
non-neoplastic T cell component in human B-
NHLs. 1,2,5,6 There is controversy both on the predom-
inant T cell population present within B-NHLs, and
on the location ofthese T cells relative to the neoplas-
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nocytes and thymocytes. As assayed by tritiated thymi-
dine incorporation, both spleen and thymus cells pro-
liferated in the presence ofCH44.LX supernatant. Al-
though supernatant from two ofnine other B cell lines
was able to stimulate the proliferation of spleen cells,
only CH44.LX could induce proliferation of thymus
cells. Supernatant from the seven other B cell lines and
three hybridomas had no measurable effect on either
splenocytes or thymocytes in this assay. It is hypothe-
sized that the presence of a non-neoplastic proliferat-
ingT cell population associated with a neoplastic B cell
lymphoma during in vivo passaging ofthe tumor is the
result ofeffects derived from a secreted product ofthe
malignant B cells. Whether the T cells have any effect
on the growth of the malignant B cells is not known.
(AmJ Pathol 1988, 133:507-515)
tic B cells. No functional studies have been done, and
the role of the non-neoplastic T cells admixed with
the B lymphoma cells is still unclear. Pattengale and
Taylor suggest that correlations of immunomorpho-
logic examination of involved tissues in murine lym-
phomas with phenotypic evaluation of the cells is a
useful experimental model for human lymphomas.7
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This can be augmented with functional evaluation of
the component populations.
In this study, a murine B cell lymphoma that has
an associated T cell component was evaluated to de-
termine the mechanism by which neoplastic B cells
induce the influx or proliferation of non-neoplastic T
cells. The murine B cell lymphoma, CH44, which
grows predominantly in the spleen was immunophe-
notyped both in tissue sections and cell suspensions
derived from tumor-bearing spleen. T cells comprise
15-30% ofthe total lymphoid population within a tu-
mor-bearing spleen. The T cells are nonmalignant,
nonclonal, and are found in the growing tumor even
after multiple transplant generations in histocompati-
ble mice.'0 Analysis ofgene rearrangements ofthe im-
munoglobulin heavy and light chains, and the con-
stant region ofthe T cell receptor beta chain, confirm
the diagnosis of a monoclonal B cell neoplasm with
an associated non-neoplastic polyclonal T cell popu-
lation.'0 Supernatant derived from an in vitro line of
CH44 (CH44.LX) was found to induce proliferation
of normal mouse thymocytes and splenocytes. These
data have revealed a polyclonal proliferation of nor-
mal host T cells induced by a product secreted by the
neoplastic B cells. The T cell proliferation does not
represent a specific immunologic host response to the
neoplastic proliferation ofB cells, but a response to a




All mice were bred and housed in our mouse colony
at the University of North Carolina at Chapel Hill.
Bl0.H-2aH-4bp/Wts (2a4b) have been derived from
selected F2 progeny of B10.A X B 10. 129 (21M) mice
as described.8
Tumors
CH44 is a murine B cell lymphoma derived from a
BI0.H-2aH-4bp/Wts mouse (2a4b) after a SRBC-hy-
perimmunization protocol that has been described
previously.9 This tumor is a follicular center cell lym-
phoma of the diffuse noncleaved large cell type.
CH44, an IgM, kappa, Ly- 1 positive tumor, was called
T670 before its classification as a B cell neoplasm.'o
The immunoglobulin of CH44 recognizes the phos-
phatidyl choline moiety of membrane phospholipids
in sheep, chicken, and bromelain-treated mouse
erythrocytes as detected in a liposome binding assay. "
Continuous growth of the tumor in vivo was main-
tained by serial transplantation in histocompatible
mice using intraperitoneal injection of 106 to I07 cells.
Mice were checked two to three times a week for
growth ofthe tumor by palpation ofthe spleen.
Antibodies
Directly biotinylated antibodies were used in all ex-
periments. Goat anti-mouse IgM, heavy and light
chain, was purchased from Cappell Laboratories
(West Chester, PA). The monoclonal antibodies anti-
Thyl .2 (clone 30H 1212), anti-Lyt-2 (clone 53-6.7 12)
were obtained as biotin conjugates from Becton-Dick-
inson Immunocytometry Systems (Mountain View,
CA). Biotin conjugates of anti-Ly- 1 (clone 53-7.3 12),
and anti-L3T4 (GK1.513) were made from affinity-
purified hybridoma supernatants as described by
Warnke and Levy.'6 The streptavidin-phycoerythrin
conjugate used as the second step reagent in immuno-
fluorescence was purchased from Becton-Dickinson
Immunocytometry Systems (BDIS, Mountain
View, CA).
In Vitro Lines
The in vitro-adapted cell line ofCH44 (CH44.LX)
has been maintained in tissue culture for more than a
year. It is passed two to three times a week in RPMI
1640 (Grand Island Biological Co. [GIBCO], Grand
Island, NY) supplemented with 50 uM 2-mercapto-
ethanol, 10% fetal bovine serum (FBS), and 100 mM
glutamine. This growth medium is called B cell me-
dium (BCM). No antibiotics are used in this medium.
Other B cell lines used in this study were grown in B
cell medium also. Supernatants for use in lymphocyte
stimulation assays were derived from cell lines grown
to high density.
Hybridoma cells were grown in DMEM (GIBCO)
supplemented with 10% FBS, 100 mM glutamine,
and nonessential amino acids.
Immunofluorescence
Cells for analysis by flow cytometry were from
splenic tissue. A single-cell suspension was made by
pressing the tissue gently between two glass slides,
then passing the cells through nylon mesh (Nitex, HC
3-100, Tetko, Inc., Elmsford, NY). Erythrocytes were
depleted by lysis using Gey's buffer."4 A total of 106
cells in 100 IL were incubated with a saturating con-
centration of directly biotinylated primary antibody
in the well of a 96-well microtiter plate, followed by
phycoerythrin-streptavidin (BDIS). Immunofluores-
cence of 10,000 cells was measured by flow cytometry
AJP * December 1988
NON-NEOPLASTIC T CELLS IN A B CELL LYMPHOMA
using an EPICS V fluorescence-activated cell sorter
(Coulter Diagnostics, Hialeah, FL). Three hundred
milliwatts of the 488 nm line of the argon laser was
used for excitation ofphycoerythrin. Cells for analysis
were selected on the basis of 900 light scatter (900 LS)
vs. forward angle (FALS) light scatter. Dead cells were
gated out by their characteristic low light scatter pro-
file. 5
Immunohistology
Immunophenotyping of lymphoid cells in frozen
tissue sections was done by a modification of the
method ofWarnke and Levy. 16 Tissues, embedded in
OCT compound (Miles Laboratories, Naperville, IL),
were snap frozen. Frozen tissue sections, cut at 5-6 u,
were incubated with a blocking serum containing 5%
(vol/vol) normal goat serum, 5% (vol/vol) normal rat
serum, 2% (vol/vol) normal mouse serum and 2%
(vol/vol) BSA, followed by biotinylated primary anti-
body for various predetermined optimum periods of
time and temperatures. Binding of primary antibody
was followed by an avidin-biotin-peroxidase complex
(Vector Laboratories, Burlingame, CA), then with the
peroxidase substrate 3-amino-9-ethylcarbazole (AEC,
Sigma, St. Louis, MO). Controls, which were invari-
ably negative, consisted of rat monoclonal antibody
30C7 as the first step instead of primary antibody.
This antibody is directed to the allelic form of the
Lgp 100 (Ly9. 1) molecule, which is not found on BI 0
strains of mice.'2 Staining of liver tissue required an
avidin-biotin blocking step. This avidin-biotin flush
technique'7 inhibited high background staining ofthe
tissue due to the presence of endogenous biotin. The
avidin-biotin blocking kit was purchased from Vector
Laboratories.
In Vitro Stimulation of Normal Cells
Thymus or spleen cells from a young mouse (less
than 3 months ofage) were depleted ofred blood cells,
and adjusted to 4 X 106 cells per ml. One hundred
microliters of cells (4 X I05 cells) were placed in each
well ofa 96-well plate. An equal volume of log serially
diluted filtered supernatant from in vitro cell lines was
added to each of triplicate wells. The final concentra-
tion of tissue culture supernatant ranged from 0.001-
50% of the total volume of 200 ,l. Mitogen control
wells contained LPS (4 ,ug/ml), PHA (10 ,ug/ml), or
CON-A (5 ,ug/ml). After 1-5 days incubation, 1 ,uCi
of 3H-thymidine (3H-TDR, New England Nuclear
Corp., Boston, MA, specific activity 5.0 Ci/mmole)
was added to each well. The samples were harvested
onto filter paper discs 16-18 hours later. Counts per
Table 1 -Subsets of T Cells in the Enlarged Spleens of Mice
Bearing the CH44 Lymphoma








51 t 24 30 33 17
65 17 15 20 8
49 19 25 30 15
77 0 NAI" NA NA
* Surface antigens analyzed by flow cytometry on cells in suspension. For
details see Materials and Methods.
t Percent positive cells determined by immunofluorescence. The calcula-
tion of percent positive cells was determined by subtracting the number of
cells falling under the negative control portion of the histogram from the total
number of cells times 100.
t Both CH44 tumor-bearing spleens analyzed were taken at the 12th
transplant generation after the primary tumor.
§ T837 is a B cell lymphoma of 2M4b origin. These data are derived from
analysis of the first generation tumor after the primary tumor (kindly provided
by Dr. Nancy Van Houten).
"I Not applicable.
minute (cpm) of incorporated 3H-TDR were assayed
using a Beckman scintillation counter. All results rep-
resent the mean of triplicate cultures.
Results
Fluorescence Analysis
Immunophenotype analysis of cell suspensions
made from spleens containing the CH44 lymphoma
indicated the presence of both B and T cells. Growth
of the CH44 lymphoma in vivo was maintained by
serial transplantation of the tumor cells in histocom-
patible mice. CH44 is a very slow-growing tumor. It
often takes more than 2 months for the spleen to grow
to 1 g or more in size. Previous immunophenotyping
ofCH44 showed that T cells were present in both early
and late transplant generations after the primary tu-
mor, and in moderately and grossly enlarged spleens,
those from 6 to more than 20 times the size of a nor-
mal spleen.'0 To determine if the size of the tumor
influenced the phenotype ofthe T cells present, ie, the
ratio ofhelper to cytotoxic/suppressor cells, CH44 tu-
mor-bearing spleens were removed from mice at
different time points during the same transplant gen-
eration. Table 1 shows the quantitation of lymphoid
cell subpopulations in CH44-containing spleens of
0.6 g and 2.1 g. This is compared with a normal
spleen, which weighs 50-100 mg, and a B cell lym-
phoma T837, which does not contain a significant T
cell component. These CH44 spleens represent tissue
from the 12th transplant generation after the primary
tumor.
Phenotypic analysis ofthe T cell subpopulations by
flow cytometry revealed the presence of both helper
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Figure 1-Immunophenotypic analysis of a normal 2a4b spleen and a 2.1 g
CH44-bearing spleen by flow cytometry. The frequency and fluorescence
intensity of the stained cells were determined using an EPICS V fluores-
cence-activated cell sorter (Coulter Electronics, Hialeah, FL). Binding of di-
rectly-biotinylated antibodies to cells was visualized with phycoerythrin-
streptavidin (Becton-Dickinson Immunocytometry Systems, Mountain View,
CA). Ten thousand viable cells (gated by forward and 900 light scatter) were
analyzed for each antibody. A-Normal spleen, 50-100 mg. B-
CH44 spleen, 2.1 g. Neg and short arrow, negative control; open arrow, B
cells, IgM+; closed arrow, T cells, Thyl.2+.
and cytotoxic/suppressor populations. Figure 1 shows
the flow cytometric histograms obtained from analy-
sis on a suspension of normal splenocytes (Figure 1 A)
and the 2.1 g CH44 tumor-bearing spleen (Figure 1 B).
In normal mouse spleens, we have found that IgM+
cells account for 40-60% of the total lymphoid cells,
while Thy 1.2+ cells range from 20-40% ofthe splenic
lymphoid cells. The tumorous CH44 spleens, regard-
less of size, contained approximately 20% T cells.
Most lymphomas from 2a4b mice are classified as tu-
mors derived from cells of the B cell lineage if the
splenic tumor-bearing tissue contains more than 85%
IgM positive cells in the cell suspension. In most cases,
these tumors are classified as B lymphomas by the sec-
ond or third generation after the primary tumor.
CH44 tumor-bearing tissue consistently contained a
significant non-neoplastic T cell component even af-
ter more than ten transplant generations from the pri-
mary tumor.
The helper (TH, CD4, Lyl/L3T4+) to cytotoxic/
suppressor (Tc/s, CD8, Lyt2+) ratio ofthe T cell popu-
lation associated with CH44 was found to be approxi-
mately 2.0. This was true in the CH44 tumor-bearing
spleens whether the tumorous spleen was 5 or 25
times the weight of a normal spleen. This CD4:CD8
ratio is the same as we generally find in a normal 2a4b
mouse spleen. Although the ratio ofT cells to B cells
did not increase in the splenic tissue with increasing
spleen size, there was a marked increase in the total
number of T cells in the massively enlarged spleens.
These data indicate that there is not a selective in-
crease in one subpopulation of T lymphocytes with
CH44, but that both subpopulations ofT cells are in-
creased in number in a growing CH44 tumor.
Immunohistochemical Analysis ofCH44
That both T helper and T cytotoxic/suppressor cells
are found in approximately the same frequency in a
greatly enlarged CH44 tumor-bearing spleen as com-
pared with a moderately enlarged CH44 tumor-bear-
ing spleen and with that seen in normal spleens, im-
plies that an active proliferation or recruitment ofthe
T cell population is occurring. Otherwise the propor-
tion of T cells would decrease as the number of neo-
plastic B cells increased. To investigate the possibility
that there was a selective spatial association of one
subpopulation of T lymphocytes with the CH44 tu-
mor cells within the tumor tissue, we stained frozen
tissue sections of CH44 tumor tissue for surface im-
munoglobulin (slg) as well as T cell differentiation an-
tigens. This type of analysis is not a quantitative
method ofdetermining cell phenotypes, but does give
information on the identification and arrangement of
cell types relative to each other, and it is semiquantita-
tive.
CH44 grows as a diffuse lymphoma. The normal
splenic architecture seen as defined areas of red pulp
and white pulp is effaced. The nodules of white pulp
are no longer identified as accumulations of lympho-
cytes located near central arterioles. Both Ly- 1 /L3T4+
and Lyt-2+ T cells were easily identifiable in the
splenic tissue sections of CH44 tumor tissue. The T
cells were found most often as local accumulations of
T cells located near the central artery (Figure 2). A
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Figure 2-Light and immunoperoxidase microscopy of the CH44 B cell lymphoma in a 2.1 g spleen (X450). For details of the procedure see Materials and
Methods. A-Hematoxylin and eosin stain seen by light microscopy showing large neoplastic lymphocytes and focal infiltrate of small lymphocytes, most
numerous at the top of the photomicrograph. B-Same spleen immunostained with anti-lgM showing staining of the neoplastic B cells, but no staining of
non-neoplastic T lymphocytes. C-Same spleen immunostained with anti-Thy 1.2 showing positive staining of the non-neoplastic T lymphocytes, and
negative staining of the neoplastic B cells.
smaller number of T cells were found admixed with
the malignant B cells. These T cells generally were of
the helper phenotype. Thus, although the diffuse
growth of the tumor resulted in the loss of follicular
structure of lymphoid tissue, the accumulations ofT
cells remained near the central arterioles, as in normal
splenic white pulp.
The markedly increased absolute number ofT cells
in the spleen indicates that they are not merely resid-
ual lymphocytes of the spleen, but are the result of
recruitment or proliferation. Thus, we decided to look
for a T cell-associated population with the CH44 tu-
mor cells at an extranodal site that normally does not
contain substantial- numbers of mature lymphocytes,
the liver. Immunophenotyping of normal liver sec-
tions for B and T cells revealed negligible numbers of
either type of lymphocyte. When CH44 tumor cells
grew in the liver, however, T lymphocytes were also
present. Table 2 shows the quantitation ofB cells and
T cells in normal and tumor bearing liver. Normal
liver tissue contains essentially no lymphocytes. Al-
though the B cell lymphoma CH7 did invade liver tis-
sue extensively, it did not contain a T cell component.
Liver tissue in which CH44 tumor cells have invaded
contains both B cells and T cells. This indicated that
the presence of the neoplastic B cells in some way in-
duced the influx or proliferation of non-neoplastic T
cells. In other words, a nonmalignant T cell popula-
tion accompanies the growth of the malignant B cell
population, even at sites not normally populated by T
cells.
Induced Proliferation of Normal Cells
For investigation of the possibility that the CH44
tumor cells secrete a product that could induce nor-
mal lymphocytes to proliferate, stimulation ofnormal
mouse spleen or thymus cells by CH44 was assayed in
a tritiated thymidine incorporation assay. Either
spleen or thymus cells from 2a4b mice were cultured
with supernatant from the in vitro cell line of CH44
(CH44.LX). Addition of CH44.LX supernatant in-
duced the proliferation of both thymus and spleen
cells. Figure 3 shows a time course analysis of the in-
duced proliferation of 2M4b splenocytes and thymo-
cytes.
Table 2-Enumeration of Lymphocytes in Liver Tissue Sections
Tissue* B cellst T celist
CH44 4.5/HPF 2.4/HPF
CH7 >25/HPF <5/section/HPF
Normal liver 0/section/LPF O/section/LPF
* Liver tissue sections from mice carrying a fatal B cell lymphoma or nor-
mal liver tissue.
t Cells staining positively with anti-lgM antibody.
t Cells staining positively with anti-Thy 1.2 antibody.
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Figure 3-Time course analysis of tritiated thy-
midine incorporation assay showing induced
proliferation of normal mouse cells by CH44.LX
supematant. Normal splenocytes or thymo-
cytes from a 6-12-week-old mouse were cul-
tured for up to 5 days in a total volume of 200
,ul. At the end of each day's incubation, 1 jCi of
3H-TDR was added to a set of wells, and the
cells were harvested 16 hours later. The data
are presented as log percent (%) supematant
vs. counts per minute (cpm) of incorporated thy-
midine. Each value represents the mean of tripli-
cate cultures. Control values for spleen cells are
cpm x 10-4. A-Spleen cells. B-Thy-
mus cells.
Log Percent Supernotant
Proliferation of thymocytes was not evident until
the cells had been cultured in the presence of
CH44.LX supernatant for more than 40 hours. After
2 days, normal thymocytes proliferated in the pres-
ence of 10 or 50% CH44.LX supernatant. The opti-
mum response of thymocytes was seen on day 3. 3H-
TDR incorporation by thymocytes cultured with
CH44.LX showed a linear dose-response relationship
on day 3, and also on days 4 and 5 except at the two
highest concentrations. By day 5, as little as 1 part in
10,000 of CH44.LX supernatant in the total 200 ,ul
culture would induce measurable proliferation ofthy-
mus cells.
Table 3-Comparison of Ability of Supernatants from Various in
vitro Lines and Serum to Induce Proliferation of Normal Spleen
and Thymus Cells as Assayed by the Tritiated Thymidine
Incorporation Assay
Supernatant Spleen Thymus Description
CH44.LX* +t + IgM, Kappa, Lt
CH12.LX + - IgM, Kappa, L
OO.LX§ + - IgM, Kappa, L
CH1.LX - - IgM, Lambda, L
CH2.LX - - IgM, Lambda, L
CH7.LX - - IgM, Kappa, L
CH27.LX - - IgM, Kappa, L
CH31.LX - - IgM, Kappa, L
CH37.LX - - IgG, Kappa, L
WEHI231" - - IgM, Kappa, L
30C7 - - MAbI anti-Lgpl00 lgG2a
14-4-4S - - MAb anti-l-Ek lgG2a
HO13.4 - - MAb anti-Thyl IgM
CH44 serum - - Spleen = 0.6 g
CH12 serum - - Spleen = 0.4g
Mouse serum - - Normal
* CH = B cell lymphomas of H-2a origin.
t +/- represents positive or negative effects of the added supematant in
the induced proliferation of spleen or thymus cells. A negative result indi-
cates that there was no incorporation of 3H-TDR above background values
of the medium only control.
t L, lymphoma.
§ OO.LX, spontaneous B cell lymphoma of H-2a origin.
"WEHI, B cell lymphoma of H-2d origin.
'Monoclonal antibodies with specificity and antibody isotype described.
The proliferative response of spleen cells in the
presence of CH44.LX supernatant was not as dra-
matic as that of thymocytes. Supernatants from two
of nine other cultured B lymphoma cell lines were
able to induce proliferation of normal mouse spleen
cells (Table 3 and Figure 4). Supernatant from the B
cell lymphomas CH12.LX (H-2a) and OO.LX (H-
2aTh) induced significant proliferation ofspleen cells as
assayed by tritiated thymidine incorporation; how-
ever, six supernatants from B cell lines ofH-2a origin,
as well as one of H-2d origin, were not able to induce
proliferation of either spleen or thymus cells. Super-
natants from three hybridomas containing mono-
clonal antibodies ofdiverse origin and immunoglobu-
lin isotype were tested. They also had no proliferative
effect on either spleen or thymus cells. All tissue cul-
ture supernatants were produced in the same manner;
however, the stimulatory effects of blastogenesis were
seen with the supernatants from three ofnine cell lines
on splenocytes (CH44.LX, CH 12.LX, and OO.LX),
and from only one of nine cell lines on thymocytes
(CH44.LX).
Finally, serum from mice carrying a large tumor
burden ofCH44 or CH 12 was tested in the prolifera-
tion assay. Neither tumor released amounts ofthe fac-
tor into the serum of a tumor-bearing animal that
would stimulate the proliferation of splenocytes and
thymocytes that could be detected by this assay. Thus,
ofall supernatants and sera tested, only CH44.LX was
able to induce proliferation of normal mouse thymo-
cytes.
Discussion
The presence and characteristics of the proliferat-
ing, non-neoplastic T cell population associated with
a monoclonal B cell lymphoma were investigated.
The results establish that a murine B cell lymphoma,
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Figure 4-Stimulation of normal murine spleno-
cytes and thymocytes with supematants from
in vitro murine B cell lymphoma cell lines mea-
sured by tritiated thymidine incorporation. Nor-
mal splenocytes or thymocytes from a 6-12-
week-old 2%4b mouse were incubated in the
presence of filtered supematant from CH44.LX
(rectangle), CH12.LX (star), or 00w.LX (poly-
gon). After 3 days, 1 ACi 3H-TDR was added to
each well, and the cells were harvested 16-18
hours later. The data are presented as log per-
cent (%) supematant vs. counts per minuted of
incorporated thymidine. Each value represents
the mean of triplicate cultures. Control values
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CH44, produces a secreted product that induces nor-
mal thymocytes and splenic lymphocytes to prolifer-
ate. In vivo growth ofCH44 is localized mainly in the
spleen, and is associated with a non-neoplastic poly-
clonal proliferating T cell population. The T cells have
been shown to be a polyclonal, non-neoplastic, host-
derived population. ' CH44 tumor cells occassionally
grow in sites other than the spleen. Usually this is the
mesenteric lymph nodes, but growth in some periph-
eral nodes, the Peyer's patches, and the liver has been
seen. An increase in the T cell population accompa-
nies the growth ofCH44 at these sites. Even the liver,
which normally contains a negligible number ofT or
B cells, has substantial numbers ofT cells when malig-
nant B cells are present.
To gain an understanding ofthe functional basis for
the continuing presence ofT cells with the malignant
B cells, we first needed to characterize the T cells. Inte-
gration of two types of immunophenotype analysis,
flow cytometric analysis on single cell suspensions
and immunohistochemical staining of frozen tissue
sections, allowed definitive evaluation of the T cell
population. The presence of both helper (CD4) and
cytotoxic/suppressor (CD8) subpopulations in the
splenic tumors was shown by both techniques. The
ratio of CD4 to CD8 cells was 2:1 in both 0.6 g and
2.0 g CH44-bearing spleens. A similar ratio is seen in
normal mouse spleens weighing 50-100 mg. This
finding indicated that there was not a selective in-
crease in one particular T cell subpopulation (CD4 vs.
CD8), but that a proliferative stimulus upon the total
T cell population was present.
An in vitro cell line of CH44 provided an explana-
tion for the T cell proliferation associated with growth
ofthis B cell lymphoma. The malignant B cells secrete
a product that induces normal spleen and thymus
cells to proliferate. The effect of CH44 supernatant is
a strong one. Incorporation of3H-TDR in thymocytes
is increased 49 times over background after 4 days in
culture with as little as 0.1% CH44.LX supernatant.
Whether the proliferative effect ofCH44.LX superna-
tant is specific for T cells or active on both B and T
cells has not been investigated. It is possible that the
product secreted by CH44 is autostimulatory, and is
thus pan-lymphoactive.
Splenic tissue from this lymphoma has a massive
nonclonal T cell proliferative component, as well as
the clonal B cell malignancy. Our data indicate that
the neoplastic B cells induce the T cell proliferation
by releasing a stimulatory factor. Thus, the T cells are
not the result of direct host immune response to the
growing B cell malignancy. This does not imply that
the T cells play no active role in controlling the neo-
plastic B cell proliferation, or in maintaining the
growth of the malignant B cells. The presence of T
cells in human diffuse B cell malignancy has been as-
sociated with a more indolent course of the disease.'8
This fact has been used to hypothesize that the T cells
are part of a beneficial host response to the growing
B cell malignancy. Alternatively, the capacity of the
neoplastic B cells to release a T cell stimulatory factor
could be a retention ofa functional capacity normally
involved in lymphoid tissue ecotaxis. Thus, this
marker of retained differentiation might correlate
with lower malignant potential.
The presence of presumably non-neoplastic T cells
in B cell lymphomas has long been recognized.2" 9 The
distribution and phenotype of lymphocyte subpopu-
lations has been analyzed using cell suspensions2'2'
and frozen tissues.5'6 Dvoretsky et al analyzed T lym-
phocyte subsets in follicular B cell lymphomas.5 The
majority ofT cells within the neoplastic follicles, and
in the interfollicular zones, were ofthe helper/inducer
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tive lymph nodes and tonsils, the frequency ofT cyto-
toxic/suppressor cells was increased as well. T cells
were found scattered in small groups or clusters within
neoplastic follicles, and did not appear activated. No
difference was found in the distribution ofT cell pop-
ulations among the various subtypes offollicular lym-
phoma analyzed, and no change in distribution ofT
cell phenotypes (CD4 vs. CD8) in treated vs. untreated
patients was seen. The portion ofT cells varied over a
wide range (20-73%), but the authors suggest that this
was due to an inverse relationship to the density ofthe
growing malignant B cell population.
Harris and Bhan characterized T cell subsets in
both follicular and diffuse B cell lymphomas.6 The T
cells in this study also appeared as normal small lym-
phocytes located in aggregates among the nodular
growths of malignant B cells. In most cases of diffuse
lymphoma, the T cells were scattered throughout the
tumor; however, in 2 of 16 large-cell tumors the T
cells appeared in clusters, suggesting a vague nodular-
ity in the growth of the tumor. The CD4:CD8 ratio
was lower in diffuse vs. nodular lymphoma, indicating
an increase in the TC/, population. Similar to CH44,
large numbers of T cells were found in five cases of
diffuse lymphomas growing in extranodal sites. This
argues, the authors say, against the T cells being
merely residual lymphoid cells. They hypothesize that
the¢- T cells may be playing a functional role in their
interactions with the malignant cells.
Lymph nodes from B-non-Hodgkin's lymphoma
(B-NHL), Hodgkin's disease (HD), and benign lym-
phoid hyperplasia were compared for the frequency
of various subsets ofT cells by Knowles and cowork-
ers.20 Generally, these authors found fewer T cells in
diffuse vs. nodular lymphomas, in agreement with
Harris and Bhan. The CD4:CD8 ratio varied widely
from case to case in HD, and less so in B-NHL, but
still ranged from 0.5-5.0. They found no correlation
between the type of tumor, its slg isotype, the clinical
stage of the disease, and the percentage of T cells
found. A significant T cell population was found in
ocular lymphomas as well. Lymphocytes are not usu-
ally found at this immunologically privileged site. The
mean ratio of CD4:CD8 cells was 2.0 at this extra-
nodal site, similar to that found in CH44 tumor-bear-
ing spleen and liver. Thus, this argues against the T
cells being a residual population of lymphocytes.
The malignant B cells may be immunogenic, and so
induce a host response to the neoplastic proliferation.
Jaffe hypothesizes that the T cell predominance in
some human B cell malignancies represents a benefi-
cial host response as recognized by the indolent course
of the disease in these patients.18 The B cells could be
specifically or nonspecifically recruiting the T cell
population into the tissue in which it is growing by a
mechanism other than immune recognition. The
non-neoplastic T cells may provide immunoregula-
tory signals or factors necessary for maintenance of
the neoplastic B cell proliferation. The malignant B
cells may be secreting an autostimulatory growth fac-
tor that also effects normal T cells.
There have been few studies combining descriptive
and functional assays ofthe different cellular compo-
nents in lymphomatous tissue. Continued propaga-
tion of the tumor in vivo, as exists in the mouse, is
not possible with human tumors. In addition, in vitro
culture methods have improved significantly for
many types of murine hematopoietic cells allowing
long-term growth of cells. CH44, available for study
as both an in vivo tumor and an in vitro cell line, pro-
vides an intriguing model for study of diffuse B cell
malignancies, and of interaction between B cells and
T cells. Analysis of the functional interactions be-
tween the malignant B cells, and non-neoplastic T
cells, and a determination of the clonality of the T
cells, has been lacking from studies ofhuman lympho-
mas, but has been initiated in this murine lymphoma.
The importance and function of the host-derived T
cells infiltrating the B cell lymphoma is not known.
An understanding of the in vivo relationship of the
malignant B cells and the associated non-neoplastic
populations may aid the understanding of normal
lymphoid immunoregulatory interactions, or to plan
effective immunotherapeutic regimens. This study
provides evidence that the nonmalignant T cell popu-
lation associated with a known monoclonal B cell ma-
lignancy is derived from a stimulus to proliferation
provided by the malignant B cells. Whether the T cells
can or do interact functionally with the B cells is a
question for future studies.
References
1. Habeshaw JA, Bailey D, Stansfeld AG, Greaves MF:
The cellular content of non-Hodgkin's lymphomas: A
comprehensive analysis using monoclonal antibodies
and other surface markers. Brit J Cancer 1983, 47:327-
351
2. Jaffe WS, Braylan RC, Nanba K, Frank MM, Berard
CW: Functional markers: A new perspective on malig-
nant lymphomas. Cancer Treat Rep 1979, 61:953-962
3. Lukes RJ, Parker JW, Taylor CR, Tindle BH, Cramer
AS, Lincoln TL: Immunologic approach to non-Hodg-
kin's lymphoma and related leukemias: Analysis of the
results of multiparameter studies of 425 cases. Sem
Hematol 1978, 15:322-351
4. Arnold A, Cossman J, Bakhshi A, Jaffe ES, Waldmann
TA, Korsmeyer SJ: Immunoglobulin-gene rearrange-
ments as unique clonal markers in human lymphoid
neoplasms. N Engl J Med 1983, 309:1593-1599
Vol. 133 * No.3 NON-NEOPLASTIC T CELLS IN A B CELL LYMPHOMA 515
5. Dvoretsky P, Wood GS, Levy R, Warnke RA: T-lym-
phocyte subsets in follicular lymphomas compared
with those in non-neoplastic lymph nodes and tonsils.
Hum Pathol 1982, 13:618-625
6. Harris NL, Bhan AK: Distribution of T-cell subsets in
follicular and diffuse lymphomas of B-cell type. Am J
Path 1983, 113:172-180
7. Pattengale PK, Taylor CR: Experimental models of
lymphoproliferative disease: The mouse as a model for
human non-Hodgkin's lymphomas and related leuke-
mias. Am J Pathol 1983, 113:237-265
8. Wettstein PJ, Haughton G: Production, testing, and
utility ofdouble congenic mouse strains. I. B l O.H-2aH-
4bp/Wts and BIO.H-2dH-4bp/WtS. Transplantation
1974, 17:513-521
9. Lanier LL, Arnold LW, Raybourne RB, Russell S,
Lynes MA, Warner NL, Haughton G: Transplantable
B cell lymphomas in BlO.H-2aH-4bp/Wts mice. Immu-
nogenetics 1982, 16:367-371
10. Willoughby PB, Haughton G: The mixed phenotype
lymphomas of BlO.H-2aH-4bp/WtS mice: Character-
ization ofcomponent cell populations. J National Can-
cer Institute 1988, 80:351-360
11. Mercolino TJ, Arnold LW, Haughton G: Phosphatidyl
choline is recognized by a series of Ly- 1 + murine B cell
lymphomas specific for erythrocyte membranes. J Exp
Med 1986, 163:155-165
12. Ledbetter JA, Herzenberg LA: Xenogeneic monoclonal
antibodies to mouse lymphoid differentiation antigens.
Immunol Reviews 1979, 47:63-90
13. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans
J, Loken MR, Pierres M, Fitch FW: Characterization of
the murine T cell surface molecule, designated L3T4,
identified by monoclonal antibody GKI.5: Similarity
ofL3T4 to the human Leu-3/T4 molecule. J Immunol
1983, 131:2445-2451
14. Mishell BB, Shiigi SM (eds): Selected Methods in Cellu-
lar Immunology. San Francisco, WH Freeman and Co
1980, pp 23-24
15. Herzenberg LA, Herzenberg LA: Analysis and separa-
tion using the fluorescence-activated cell sorter, Hand-
book of Experimental Immunology. Edited by DW
Weir. London, Blackwell Scientific Publications, 1986,
pp 221
16. Wamke R, Levy R: Detection ofT and B antigens with
hybridoma monoclonal antibodies: A biotin-avidin
horseradish peroxidase method. J Histochem Cyto-
chem 1980, 28:771-776
17. Wood G, Warnke R: Suppression of endogenous avi-
din-binding activity in tissues and its relevance to bio-
tin-avidin detection systems. J Histochem Cytochem
1981, 29:1196-1204
18. Jaffe ES: Pathologic and clinical spectrum of post-
thymic T cell malignancies. Cancer Invest 1984,2:413-
426
19. Filippa DA, Leiberman PH, Erlandson RA, Koziner B,
Siegal FP, Turnbull A, Zimring A, Good RA: A study
of malignant lymphomas using light and ultramicro-
scopic, cytochemical and immunologic technics. Am J
Med 1978, 64:259-268
20. Knowles DM, Halper JP, Jakobiec FA: T-lymphocyte
subpopulations in B-cell-derived non-Hodgkin's lym-
phomas and Hodgkin's disease. Cancer 1984, 54:644-
651
